Consecutive weekly or biweekly serum specimens obtained during a 3-or 4-month study from 16 chimpanzees were examined by immunoblot analyses to identify the immunogenic components of Mycoplasma pneumoniae. Six experimentally infected chimpanzees showed significant signs of overt disease, including cough, pharyngitis, rhinitis, fever, and loss of appetite. The sera of these infected chimpanzees recognized from 17 to 20 protein bands. Two control chimpanzees that were not inoculated were included in the study. Three chimpanzees immunized with a formalin-inactivated OSU-1A vaccine and three chimpanzees immunized with an experimental acellular vaccine showed minimal signs of disease on challenge. After challenge, the serum immunoblot responses of the immunized chimpanzees were similar to those of the infected chimpanzees. Before challenge, the sera of two previously infected chimpanzees recognized protein bands of 169 (which comigrated with the P1 adhesin), 148, 130, 117, 86, 61, 44, 35, 30 , and 29 kDa. After challenge, the previously infected chimpanzees showed the most intense serum immunoblot responses and were most protected against colonization and disease. The sera from each of the 16 chimpanzees examined recognized a large number of immunogenic components, and the serum immunoblot responses were virtually identical to those of patients. Sera from each chimpanzee and patient recognized 169-, 148-, 130-, 117-, 86-, 44-, and 35-kDa bands and many of them recognized 67-, 63-, 61-, 56-, 32-, 30-, and 29-kDa protein bands.
The sera examined in this study were collected in two previous studies (4, 5, 7) . In the first study, six chimpanzees were experimentally infected with Mycoplasma pneumoniae and showed overt signs of disease that corresponded with peak lung colonization, the development of cold agglutinins, and positive X-ray findings (4) . The clinical, microbiological, and serological aspects of the disease were similar to those of patients with primary atypical pneumonia. Two negative control chimpanzees that were not inoculated were included in the study (4) . In the second study, three additional chimpanzees were immunized with an OSU-1A formalin-inactivated vaccine, and three were immunized with an experimental acellular vaccine (5) . The six immunized chimpanzees showed less disease than two unimmunized controls on challenge (5) .
The same lot of the OSU-1A formalin-inactivated vaccine (5) was used earlier in a hamster immunization challenge potency assay (3) and a human clinical trial (57) . The experimental acellular extract vaccine contained attachment, ciliotoxic, and leukocyte recruitment activities (13, 15) , and it protected immunized hamsters against colonization and the development of lung lesions on challenge (3). Two chimpanzees infected in the first study (4) were challenged in the second study (5) to determine whether a previous infection protected against a subsequent challenge. The two previously infected chimpanzees showed no detectable indication of disease and were virtually free of colonization.
The purpose of the present study was to identify the immunogenic components of M. pneumoniae by analyzing and comparing the immunoblot responses of sera obtained from 16 address: FBS@NIHcu. chimpanzees that were unimmunized and unprotected, immunized and partially protected, or previously infected and fully protected on challenge.
MATERIALS AND METHODS
M. pneumoniae. M. pneumoniae PI-1428 was used previously to experimentally infect guinea pigs (11, 12) , hamsters (2, 3), Cercopithecus (African green) and Macaca (rhesus) monkeys (28) , human volunteers (19, 48, 49) , and chimpanzees (4, 5) . Strain PI-1428 was also shown to attach avidly to cell cultures (14, 17) . The organism was grown in a modified EdwardHayflick medium containing a rich basal medium, 15% horse serum, and 5% yeast extract (1) . The preparation of the mycoplasma antigen and the negative antigen control (complete sterile broth medium) used in these studies was described earlier (27) .
Chimpanzees. The treatments and experimental protocols of the chimpanzees examined (4, 5) are summarized in Table 1 . Although 16 animals were used, two chimpanzees (854 and 881) were used in both studies. They were infected in the first study and challenged in the second study to determine whether a previous infection protected against a subsequent challenge.
Vaccines. The same lot of the formalin-inactivated OSU-1A vaccine used to immunize the group 4 chimpanzees was used earlier in the human clinical trials (57) . Each immunizing dose contained 1.0 mg of protein suspended in 3 ml of phosphatebuffered saline (PBS; pH 7.2). The experimental acellular vaccine administered to the group 5 chimpanzees consisted of a soluble, protein-rich, acellular extract of virulent strain PI-1428 of M. pneumoniae that contains attachment, ciliotoxic, and leukocyte recruitment activities (14, 15) 7 Sterile broth instead of 1161 2D 5 vaccine, challenged and infected (4, 5) . In brief, following inoculation with strain PI-1428, sera were obtained from the six experimentally infected chimpanzees (groups 1 and 2 [ Table 1 ]) and the two negative controls (group 3) twice a week for the first month and weekly thereafter for 16 weeks (4). Sera from the six immunized (groups 4 and 5), two previously infected (group 6), and two positive control chimpanzees (group 7) were obtained at -5 weeks (before the first immunizing dose), -2 weeks (before the second immunizing dose), day 0, before challenge, weekly for the next 4 weeks, and biweekly thereafter for 16 weeks (5). Although immunoblots were done on each serum sample collected from each of the 18 treated chimpanzees, the results are given only for sera obtained at 0, 1, 2, 4, 6, 9, and 12 weeks for the group 1 to 3 chimpanzees and at -5, -2, 0, 1, 3, 6, 10, and 16 weeks for the group 4 to 7 chimpanzees. Moreover, the data presented in this report are given for only one representative chimpanzee in each of the seven groups (Table 1) .
Human sera. Paired acute-and convalescent-phase sera of a patient with primary atypical pneumonia were kindly supplied by George Kenny, Seattle, Wash. The diagnosis was based on a fourfold increase in antibody titer and direct isolation of M.
pneumoniae.
SDS-PAGE and immunoblot analyses. The polypeptide patterns were examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as described by Laemmli (43), with 12% nongradient or 10 to 20% gradient gels as described by us earlier (27, 36) . In brief, the protein profiles were examined with 12% nongradient or 10 to 20% gels (12 by 16 cm) and a total of 500 ,ug of mycoplasma protein. Following electrophoresis, the proteins were transferred to nitrocellulose membranes. The nitrocellulose blots were subsequently stained by ponceau red, air dried, and cut into 5-mm-thick strips. Each strip was incubated for 3 to 4 h in a standard blocking solution and then incubated overnight with a 1:100 dilution of serum in the blocking solution. Blots were rinsed three times (20 min each time) with the blocking solution and incubated for 4 additional h with "NI-labeled anti-human immunoglobulin G antibody (1:500). The blots were rinsed extensively once with blocking solution and three times with PBS, air dried, and then exposed to film. The anti-human immunoglobulin G secondary antibody ( Fig. 1A and B, respectively. Before inoculation, the sera of five chimpanzees showed no detectable response, but a sixth chimpanzee, number 957 (group 2), recognized a major 63-kDa band and two minor (56-and 44- (ii) Noninoculated, negative controls. Although various precautions were taken to minimize direct contact between the inoculated group 1A and 1B chimpanzees and the noninoculated control group 1C chimpanzees, the two controls inoculated with sterile broth instead of organisms became inadvertently infected on day 19 (chimpanzee 856) and day 48 (chimpanzee 1110) of the study (4) . The serum antibody responses were similar to, but less intense than, the group 1A and 1B inoculated chimpanzees. The serum immunoblot response of representative chimpanzee 1110 is shown in Fig. 1C .
The control chimpanzees were housed in individual cages and quartered in a separate room away from the inoculated chimpanzees. All implements were sterilized before use in each animal, and aseptic procedures were maintained throughout the study. Controls were examined first throughout the study. Despite these precautions, the controls became colonized, developed serum antibody responses, and showed overt signs of moderate disease. Strains of M. pneumoniae isolated from the infected controls were indistinguishable from strain PI-1428 by culture and serologic procedures. Preselection examinations of these chimpanzees were negative for M. pneumoniae by culture and serology. In patients, transmission may develop among military recruits, students, and children housed in confined quarters (19, 24-26, 31, 48, 49, 57 Fig. 2A .
Acellular vaccine. Before immunization, serum of chimpanzee 918 showed an intense response to a 30-kDa protein band, and reactivity increased in intensity after challenge (data not shown). Immunization did not induce a significant serum antibody response in two of the chimpanzees (group 5), but the third chimpanzee (number 905) recognized a 67-and a 30-kDa band that increased in intensity after challenge. After challenge, the serum antibody responses were similar to those of group 1 to 4 chimpanzees. The serum immunoblot response of representative chimpanzee 1108 is shown in Fig. 2B .
Previously infected chimpanzees. Before challenge, the two previously infected chimpanzees (group 6) showed significant serum immunoblot responses to 169-, 148-, 130-, 117-, 86-, 61-, 44 Fig. 2C .
Nonimmunized, positive control chimpanzee. Following challenge, the serum antibody responses in the group 7 chimpanzees were similar to those of the group 1 to 5 chimpanzees. The serum immunoblot response of representative chimpanzee 1161 is shown in Fig. 2D .
Patient versus chimpanzee sera. Figure 3 shows the immunoblot responses of acute-and convalescent-phase sera of a patient and the pre-and postchallenge sera of representative chimpanzee 902 (group 7) and chimpanzee 903 (group 4). The acute-phase serum of the patient recognized an 86-kDa band, whereas the prechallenge chimpanzee sera showed no detectable response. However, the responses of the chimpanzees after challenge were virtually identical to those of the convalescent-phase serum of the patient. The serum of each chimpanzee recognized 169 The purpose of this study was to compare the serum immunoblot responses of 16 chimpanzees that were unimmunized and unprotected, immunized and partially protected, or previously infected and protected from disease on challenge.
Chimpanzees were used because of their close relationship to humans and because the M. pneumoniae-induced pneumonia in chimpanzees (4) was similar to naturally occurring primary atypical pneumonia in patients (18, 22, 31, 48) . Unlike the other animals examined, chimpanzees developed cold agglutinins, positive X-ray findings, and overt signs of disease.
ently infected during the study (group 3). Mr, approximate molecular weights. Weeks, time at which serum specimens were collected. 6) , and representative chimpanzee 1161 (D) that was unimmunized and challenged (group 7). Mr, approximate molecular weights. i.p. and i.t., intraperitoneal and intratracheal inoculation, respectively, of chimpanzees given either vaccine (group 2A and 2B) or sterile broth medium (group D). ch., challenge; Weeks, time at which serum specimens were collected.
In addition to M. pneunioniae, chimpanzees were used to examine the pathogenicity of several reputed human pathogens (6) , including Mycoplasma hominis (7), Mycoplasma genitalium (52, 54, 55) , and Ureaplasma urealyticlum (7, 53) . In each of these studies, the infections induced in chimpanzees have best reflected the course of the disease in humans. For these reasons, the chimpanzee was selected for the present study in an attempt to identify the immunogenic components of M. pneumoniae, and the results indicate that the serum immunoblot responses obtained with chimpanzees were virtually identical to those of patients (56) .
Except for the previously infected chimpanzees, the immunoblot responses before treatment were mostly negative, with few exceptions. The sera of several chimpanzees recognized 67-, 63-, 61-, 56-, 44-, and/or 30-kDa bands before treatment. The serum immunoblot responses after immunization were also mostly negative, with few exceptions. After immunization, chimpanzee 905 (acellular vaccine) recognized a 67-and a 30-kDa band, and reactivity to these bands increased in intensity after challenge.
Before challenge, the two previously infected chimpanzees recognized 169-, 148-, 130-, 117-, 86-, 61-, 44-, 35-, 30-, and 29-kDa protein bands. After challenge, these chimpanzees showed the most intensive serum immunoblot responses and were most protected against colonization and disease (5). The same sera also showed intense serum antibody responses by the metabolism inhibition procedure (5) . Hamsters that were previously infected with M. pneumoniae also showed intense serum metabolism inhibition antibody responses after challenge, and they were protected against colonization and the development of histologic lung disease (3) . Most patients are protected against reinfection, but immunity is considered to be short-lived (24) (25) (26) The ability of a strain to attach to target cells in vitro (14, 17, 45) has been correlated with the ability of that strain to produce disease in hamsters (3) . Attachment of M pneumoniae to the respiratory epithelium is mediated by a specialized terminal tip apparatus, and the 169-kDa P1 adhesin protein was shown to be located on the terminal tip (33) . Protease treatment resulted in the loss of P1 and the ability to attach and to produce disease. The regeneration of the P1 restored the ability to attach and to produce disease (32, 45) . Antibody specific for the P1 has been detected in convalescentphase sera of guinea pigs (38) and patients (36, 56, 58) , and the P1 adhesin protein has been considered an important immunogen (33-36, 38, 44, 51, 56) . In this study, the 169-kDa protein band (that migrated with the P1 adhesin) was recognized by serum obtained from each of the 16 chimpanzees examined.
However, attachment appears to be a complex phenomenon, and several factors are involved in adherence (8-10, 20, 23, 29, 30, 32, 37, 39-41, 45, 58) . By one-dimensional gel analysis, pathogenic strain M129-B7 and its isogenic nonpathogenic strain M129-B169 have identical protein profiles. By immunoblot analysis, the nonpathogenic strain M129-B169 does not possess the 90-and 40-kDa proteins (35, 44, 45, 51) , and it lost the ability to attach (14, 17, 45) and to produce disease (3). Franzoso et al. (27) showed that the 35-and the 86-kDa proteins identified by us were similar or identical to the 90-and the 40-kDa proteins identified by Hu et al. (35) and by Herrmann and colleagues (44, 51) . Franzoso et al. (27) also showed that the 86 (90)-and 35 (40)-kDa proteins were present in each of three pathogenic strains of M pneumoniae but were absent in the nonpathogenic strain M129-B169 (27) . In addition, the 86-and 35-kDa proteins were surface-exposed, membrane-integrated components localized on the terminal tip apparatus (27) . Because (8-10, 20, 32, 39-41) . In this study, serum from virtually each chimpanzee examined recognized a 30-and a 29-kDa protein band in pathogenic strain PI-1428. Madsen et al. (46) reported that a polypeptide with a molecular weight of 43,000 appeared to be a major component of M. pneumoniae; using a monoclonal antibody against this component, they showed that it reacted with each of 33 different clinical isolates. In this study, whereas the 43-kDa region is not very prominent in other infected animals, the serum obtiined from each of the 16 chimpanzees examined recognized a prominent band in the 44-kDa region. In the extensive study of serum of patients infected with M. pneumoniae (56) , this region was recognized by all of the human convalescent-phase serum samples obtained from the 12 patients tested. Under the conditions of our test procedures, it is possible that the 29-, the 30-, and the 44-kDa protein bands identified by us correspond to the 30-, the 32-, and the 43-kDa proteins, respectively, identified by these other investigators. However, this remains to be determined, since comparative studies were not done.
M. pneumoniae attaches to sulfated glycoconjugates (42), and two proteins (56 and 32 kDa) have been implicated in attachment to sulfated glycoconjugates. Marcus et al. (47) showed that the 56-kDa protein was an integral membrane protein by surface proteolysis, Triton X-114 partitioning, and immunoblots of membrane preparations with a monoclonal antibody described previously (16) . Using immunoelectron microscopy, Marcus et al. (47) also showed that the 56-kDa protein was localized on the neck of the tip structure of M. pneumoniae. Many of the chimpanzees examined in this study also recognized a band with an approximate molecular mass of 56 kDa.
In summary, these findings indicate that the serum immunoblot responses of the 18 treated chimpanzees examined were very similar to those of the human convalescent-phase serum samples of the 12 patients tested with naturally occurring disease as reported by Vu et al. (56) . We have also shown that the pathogenic strain PI-1428 of M. pneumoniae possesses a large number of immunogenic components. These include protein bands with approximate molecular masses of 169, 148, 130, 117, 86, 56, 35, 30 to 32, and 29 to 30 kDa. Therefore, it seems reasonable to suggest that, in addition to the P1 adhesin, a number of other immunogenic proteins might represent potentially important immunogens and that some of these components should also be considered as possible candidates for inclusion in the development of purified acellular vaccines for prevention of M. pneumoniae disease. 
